Observation Of Clinical Efficacy Of The Jinshuizishengyin For The Treatment Of Non-small Cell Lung Cancer

Objective:(1)To observe the Jinshuizisheng MDT for ?b-? stage non-small cell lung cancer patients with lung and kidney Yin deficiency type clinical benefit rate and the effect of including the clinical symptoms improved and lung tumors size changes,the main tumor markers numerical change and the influence of the side effects of chemotherapy.(2)To assess the Jinshuizishengyin engenders the clinical curative effect of combined chemotherapy and impact on patients quality of life and the influence of side effects of chemotherapy.Methods:Selection conforms to the inclusion criteria of a total of 60 patients with advanced non-small cell lung cancer,according to the clinical research methods are divided into two groups randomly,the observation group: oral Chinese medicine medicinal broth jinshuizishengyin with NP chemotherapy regimens(changchun marina + cisplatin);The control group was treated with NP chemotherapy alone,and 3 weeks was a treatment cycle,and 2 treatment cycles were observed continuously.Then,the results were observed and recorded in the two groups of patients before and after the treatment,such as symptom score,tumor size,tumor marker CEA value,KPS score,blood routine,liver and kidney function,etc.After observation,SPSS17.0 was used for statistical analysis of the data,and finally summarized and concluded.Results:(1)Comparison of two groups' TCM syndromes integral : the TCM syndromes integral of the treatment group is significantly lower than that in the control group,and the difference is statistically significant(p < 0.05).(2)Changes in the tumor:comparison between the two groups,objective and efficient(CR+PR)and disease control rate(CR+PR+SD)showed no significant difference instatistical analysis(P?0.05).(3)Tumor marker CEA: the treatment group had a significant advantage in reducing CEA value compared with the control group,and statistical analysis was statistically significant(p< 0.05).(4)KPS score: the score of treatment group was significantly higher than that in the control group,and the two groups were comparable(p < 0.05).(5)Toxic and side reactions: there was no statistically significant difference between the two groups in the reduction of hemoglobin and the impairment of liver and kidney function(p ? 0.05);In terms of leukocyte and thrombocytopenia and nausea and vomiting,the treatment group was better than the control group(p < 0.05).Conclusion:Engenders drink combined NP scheme chemotherapy in the treatment of the jinshuizishengyin ?b-? stage non-small cell lung cancer in the process,can reduce the CEA values,alleviate patients' clinical symptoms,improve quality of life and reduce adverse reaction of chemotherapy.